SCHEMBL2252452

SCHEMBL2252452

O=C(O)c1ccc2cc(CCc3cc(-c4ccc(F)cc4)ccc3C(=O)O)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.46
BAD Q92934 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.44
DCLRE1B Q9H816 2/20 0.43
DCLRE1A Q6PJP8 1/20 0.42
RARB P10826 2/20 0.41
PPARA Q07869 2/20 0.41
RARA P10276 1/20 0.41
RARG P13631 1/20 0.41
NR4A2 P43354 3/20 0.41
STING1 Q86WV6 1/20 0.40
HTR2C P28335 1/20 0.39
MCHR1 Q99705 1/20 0.39
DHODH Q02127 1/20 0.39
SLC16A3 O15427 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255248 0.90 SOX18 (0.50) BCL2L1BADMRGPRX4DCLRE1BDCLRE1A
SCHEMBL2253118 0.90 BCL2L1 (0.56) BCL2L1BADMRGPRX4DCLRE1BDCLRE1A
SCHEMBL2254854 0.89 EGFR (0.47) MRGPRX4DCLRE1BDCLRE1ARARBPPARA
SCHEMBL2251799 0.83 DCLRE1B (0.57) BCL2L1BADMRGPRX4DCLRE1BDCLRE1A
SCHEMBL2250853 0.83 DCLRE1B (0.54) BCL2L1BADMRGPRX4DCLRE1BDCLRE1A
SCHEMBL12062912 0.82 NR4A2 (0.46) BCL2L1BADNR4A2SLC16A3
SCHEMBL2258585 0.82 PTPN1 (0.47) BCL2L1BADMRGPRX4DCLRE1BDCLRE1A
SCHEMBL2255122 0.82 RARB (0.44) GRIN2DGRIN2AGRIN2BGRIN2CMRGPRX4
SCHEMBL2255006 0.82 RARB (0.47) MRGPRX4DCLRE1BDCLRE1ARARBPPARA
SCHEMBL2251911 0.82 NR1H4 (0.54) HTR2CMCHR1SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904047-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2013-01-02 EP disclosed
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 US disclosed
US-20100234456-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2010-09-16 US disclosed
US-7750004-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-06 US disclosed
EP-1904047-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-04-02 EP disclosed
US-20070135392-A1 Apoptosis promoters ABBVIE INC. 2007-06-14 US disclosed
WO-2007008627-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234456-A1 APOPTOSIS PROMOTERS MCL1, BAX, BCL2 BCL2L1 5/4885BAD 11/4885GRIN2D 4683/4885
US-20070135392-A1 Apoptosis promoters MCL1, BAX, BCL2 BCL2L1 5/4885BAD 11/4885GRIN2D 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.